<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00389506</url>
  </required_header>
  <id_info>
    <org_study_id>060240</org_study_id>
    <secondary_id>06-C-0240</secondary_id>
    <secondary_id>NCI-P6761</secondary_id>
    <secondary_id>NCI-7835</secondary_id>
    <secondary_id>CDR0000508789</secondary_id>
    <nct_id>NCT00389506</nct_id>
  </id_info>
  <brief_title>Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma</brief_title>
  <official_title>A Pilot Study of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Hodgkin's Disease After Fludarabine and Cyclophosphamide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in&#xD;
      different ways to stop the growth of cancer cells, either by killing the cells or by stopping&#xD;
      them from dividing. LMB-2 immunotoxin can find cancer cells and kill them without harming&#xD;
      normal cells. Giving fludarabine and cyclophosphamide followed by LMB-2 immunotoxin may kill&#xD;
      more cancer cells.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well giving fludarabine and cyclophosphamide&#xD;
      followed by LMB-2 immunotoxin works in treating patients with Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the feasibility of pretreatment with fludarabine phosphate and&#xD;
           cyclophosphamide in preventing neutralization of antibodies in patients with&#xD;
           CD25-positive Hodgkin's lymphoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the response rate in patients treated with LMB-2 immunotoxin.&#xD;
&#xD;
        -  Determine the response duration in patients receiving this treatment.&#xD;
&#xD;
        -  Correlate serum levels of LMB-2 immunotoxin with toxicity and response in these&#xD;
           patients.&#xD;
&#xD;
        -  Assess the development of neutralizing antibodies and the effect of these antibodies on&#xD;
           blood levels of LMB-2 immunotoxin and toxicity.&#xD;
&#xD;
        -  Correlate soluble Tac-peptide levels with treatment response in these patients.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, pilot study.&#xD;
&#xD;
      Patients receive fludarabine phosphate IV over 30 minutes and cyclophosphamide IV over 60&#xD;
      minutes on days 1-4 and filgrastim (G-CSF) subcutaneously once daily beginning on day 5 and&#xD;
      continuing until blood counts recover.&#xD;
&#xD;
      Beginning 4 weeks after completion of chemotherapy, patients receive LMB-2 immunotoxin IV&#xD;
      over 30 minutes on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in&#xD;
      the absence of disease progression.&#xD;
&#xD;
      Blood is obtained prior to and after chemotherapy and then periodically during LMB-2&#xD;
      immunotoxin therapy for pharmacokinetic studies to measure lymphocyte subsets.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of using fludarabine phosphate and cyclophosphamide to decrease neutralizing antibodies</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of serum levels of LMB-2 immunotoxin with toxicity and response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of neutralizing antibodies and its effect on blood level of LMB-2 immunotoxin and toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of soluble Tac-peptide with treatment response</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LMB-2 immunotoxin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histopathologically confirmed CD25+ Hodgkin's lymphoma&#xD;
&#xD;
               -  At least 20% of the malignant cells positive by immunohistochemistry&#xD;
&#xD;
               -  Stage II-IV disease&#xD;
&#xD;
          -  Meets the following criteria:&#xD;
&#xD;
               -  Failed standard chemotherapy&#xD;
&#xD;
               -  Not eligible for curative salvage radiotherapy or chemotherapy&#xD;
&#xD;
               -  Not eligible for or refused bone marrow transplantation&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No patient whose serum neutralizes LMB-2 immunotoxin in tissue culture, due either to&#xD;
             antitoxin or antimouse-IgG antibodies&#xD;
&#xD;
          -  No patient whose serum neutralizes &gt; 75% of the activity of 1 µg/mL of LMB-2&#xD;
             immunotoxin&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm³&#xD;
&#xD;
          -  Platelet count ≥ 50,000/mm³&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Albumin ≥ 3.0 g/dL&#xD;
&#xD;
          -  Bilirubin ≤ 2.2 mg/dL (&lt; 5 mg/dL if Gilbert's syndrome is present)&#xD;
&#xD;
          -  Creatinine ≤ 1.4 mg/dL OR creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  No uncontrolled intercurrent illness including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness or social situations that would limit study compliance&#xD;
&#xD;
          -  No HIV or hepatitis C positivity&#xD;
&#xD;
               -  Hepatitis B surface antigen positivity allowed provided patient is receiving&#xD;
                  lamivudine&#xD;
&#xD;
          -  LVEF ≥ 45%&#xD;
&#xD;
          -  DLCO ≥ 50% of normal OR FEV_1 ≥ 60% of normal&#xD;
&#xD;
          -  No active second malignancy requiring treatment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No systemic cytotoxic chemotherapy within the past 4 weeks&#xD;
&#xD;
          -  No systemic steroids (except stable doses of prednisone ≤ 20 mg/day) within the past 4&#xD;
             weeks&#xD;
&#xD;
          -  No monoclonal antibody therapy within the past 12 weeks&#xD;
&#xD;
          -  No prior LMB-2 immunotoxin&#xD;
&#xD;
          -  No concurrent warfarin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Kreitman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>October 18, 2006</study_first_submitted>
  <study_first_submitted_qc>October 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2006</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2012</last_update_posted>
  <keyword>stage II adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Immunotoxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

